Sino Biopharm, together with its subsidiaries, is a leading, innovative research and development driven pharmaceutical conglomerate in China, with a business scope that is vertically integrated including research and development, manufacturing and sales and marketing infrastructure.Our products include a variety of biological and chemical drugs, and are in a dominant position in the four major treatment fields of oncology, hepatolgy, respiratory system, surgery/analgesia.
The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2019, it was selected as the constituent stock of Hang Seng China Enterprise Index; In 2020, it was selected as a constituent of the Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect Biotechnology 50 Index and the Hang Seng China (listed in Hong Kong) 25 Index. The company has been listed in the "Top 50 Global Pharmaceutical Enterprises" published by the authoritative American magazine Pharmaceutical Manager for four consecutive years, and has been rated as the "Top 50 Best Companies in Asia Pacific" by Forbes (Asia) for three consecutive years.
The company's subordinate enterprises are located in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao and other places, and have multiple drug production bases. Since its establishment, the company has continued to achieve outstanding achievements and steady development. Its core enterprises, CTTQ Pharmaceutical Group and Beijing Tide Pharmaceutical Co., Ltd., have been among the top 100 Chinese pharmaceutical industry enterprises for many years.
Based on imitation, the company has made a comprehensive transformation to innovation, driven by innovative drugs, and the proportion of revenue has increased year by year; The internal research pipeline drives innovation and transformation, and constantly improves the technical platform; Under the leadership of the top scientific team, actively promote the process of internationalization and seize the leading international track.
The company will adhere to the mission of 'Science for a healthier world', focus on innovation, serve patients, and strive to become a leading pharmaceutical enterprise in the world. We hope to share the development achievements of the medical and health industry with people of insight, and work together to win the future!